Welcome to our dedicated page for Clene news (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Clene Inc. (Nasdaq: CLNN) is a clinical-stage biopharmaceutical leader developing novel nanocrystal therapies for neurodegenerative diseases. This page provides investors and researchers with essential updates on Clene’s progress in treating ALS, multiple sclerosis, and Parkinson’s disease through its innovative Clean-Surface Nanocrystal (CSN) platform.
Find authoritative coverage of Clene’s clinical trials, including updates on lead candidate CNM-Au8®’s impact on mitochondrial health and oxidative stress biomarkers. Track regulatory developments, partnership announcements with research institutions, and analyses of trial data from Phase 2/3 studies. Our curated news collection helps stakeholders monitor Clene’s unique approach to neurodegeneration through nanotechnology.
Key updates include progress toward FDA submissions, Expanded Access Program results, and peer-reviewed research publications. Bookmark this page for real-time access to earnings reports, strategic collaborations, and scientific presentations that demonstrate Clene’s position at the forefront of neurotherapeutic innovation.
Clene Inc. (NASDAQ: CLNN) announced significant findings at the 2023 AAN Annual Meeting regarding its treatment, CNM-Au8, for neurodegenerative diseases, specifically multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The data showcased a marked survival benefit in ALS patients, with early-stage treatment showing a 60% improvement and mid-to-late stage patients experiencing over 90% reduced death risk. In MS, the VISIONARY-MS study indicated enhancements in neurologic function and axonal integrity through various independent biomarkers. No notable safety concerns were observed. Clene is preparing for a Phase 3 study and anticipates critical new biomarker results from the HEALEY ALS Platform Trial, which will shape its regulatory strategy moving forward.
Clene Inc. (NASDAQ: CLNN) announced three presentations at the upcoming American Academy of Neurology Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will cover clinical trials demonstrating the efficacy and safety of their treatment CNM-Au8®. The studies include:
- VISIONARY-MS: A double-blind study on the efficacy of CNM-Au8 for relapsing multiple sclerosis, presented by Michael Barnett, Ph.D., on April 25.
- HEALEY ALS Trial: Results from the first four regimens of this platform trial, presented by Sabrina Paganoni, MD, Ph.D., also on April 25.
- Survival Benefit in ALS: Evidence for survival benefit with CNM-Au8 treatment, presented by James Berry, MD, MPH, on April 25.
These findings aim to support Clene's innovative approach in treating neurodegenerative diseases.
FAQ
What is the current stock price of Clene (CLNN)?
What is the market cap of Clene (CLNN)?
